Why GSK (GSK) is a Top Value Stock for the Long-Term

Zacks Investment Research highlights GSK (GSK) as a compelling value stock, citing its #2 (Buy) Zacks Rank and 'A' ratings for both Value and VGM style scores. The analysis points to an attractive forward P/E ratio of 8.93 and upward revisions to fiscal 2025 earnings estimates, with the consensus increasing by $0.10 to $4.30 per share, suggesting potential outperformance.

Analysis

GSK plc (GSK) is presented by Zacks Investment Research as a compelling investment, underscored by its #2 (Buy) Zacks Rank and a top-tier 'A' grade for its comprehensive VGM (Value, Growth, Momentum) Score. The company's strong appeal to value investors is highlighted by an 'A' Value Style Score, supported by an attractive forward Price-to-Earnings (P/E) ratio of 8.93. Further bolstering the positive outlook, GSK's fiscal 2025 earnings estimates have seen upward revisions from four analysts over the past 60 days, resulting in the Zacks Consensus Estimate rising by $0.10 to $4.30 per share. GSK also demonstrates a consistent track record of exceeding Wall Street expectations, with an average earnings surprise of 8.6%. The company operates through three primary segments: Specialty Medicines, Vaccines, and General Medicines, collectively forming its commercial operations.

Key Decisions for Investors

• Investors, particularly those employing a value-focused strategy, should consider GSK due to its #2 (Buy) Zacks Rank, 'A' Value Style Score, and a favorable forward P/E ratio of 8.93.
• The positive trend in fiscal 2025 earnings estimate revisions, with four analysts increasing their forecasts and the consensus estimate rising to $4.30, alongside a history of an 8.6% average earnings surprise, signals a strengthening fundamental outlook for GSK.
• Given the combination of a strong Zacks Rank and 'A' VGM score, which Zacks indicates has historically led to outperformance, GSK warrants consideration for inclusion on an investor's short list for potential long-term capital appreciation.